These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 12162815)

  • 1. Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector.
    Andrews JL; Shirley PS; Iverson WO; Sherer AD; Markovits JE; King L; Lyons RM; Kaleko M; Connelly S
    Hum Gene Ther; 2002 Jul; 13(11):1331-6. PubMed ID: 12162815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates.
    Brann T; Kayda D; Lyons RM; Shirley P; Roy S; Kaleko M; Smith T
    Hum Gene Ther; 1999 Dec; 10(18):2999-3011. PubMed ID: 10609660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
    Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
    Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector.
    Reddy PS; Sakhuja K; Ganesh S; Yang L; Kayda D; Brann T; Pattison S; Golightly D; Idamakanti N; Pinkstaff A; Kaloss M; Barjot C; Chamberlain JS; Kaleko M; Connelly S
    Mol Ther; 2002 Jan; 5(1):63-73. PubMed ID: 11786047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.
    Gallo-Penn AM; Shirley PS; Andrews JL; Tinlin S; Webster S; Cameron C; Hough C; Notley C; Lillicrap D; Kaleko M; Connelly S
    Blood; 2001 Jan; 97(1):107-13. PubMed ID: 11133749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.
    Connelly S; Andrews JL; Gallo-Penn AM; Tagliavacca L; Kaufman RJ; Kaleko M
    Thromb Haemost; 1999 Feb; 81(2):234-9. PubMed ID: 10063998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-level tissue-specific expression of functional human factor VIII in mice.
    Connelly S; Gardner JM; McClelland A; Kaleko M
    Hum Gene Ther; 1996 Jan; 7(2):183-95. PubMed ID: 8788169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector.
    Roy S; Shirley PS; Connelly S; Andrews JL; Kayda DB; Gardner JM; Kaleko M
    Haemophilia; 1999 Sep; 5(5):340-8. PubMed ID: 10583516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained expression of therapeutic levels of human factor VIII in mice.
    Connelly S; Gardner JM; Lyons RM; McClelland A; Kaleko M
    Blood; 1996 Jun; 87(11):4671-7. PubMed ID: 8639836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery.
    O'Neal WK; Zhou H; Morral N; Aguilar-Cordova E; Pestaner J; Langston C; Mull B; Wang Y; Beaudet AL; Lee B
    Hum Gene Ther; 1998 Jul; 9(11):1587-98. PubMed ID: 9694157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates.
    Smith TA; Idamakanti N; Marshall-Neff J; Rollence ML; Wright P; Kaloss M; King L; Mech C; Dinges L; Iverson WO; Sherer AD; Markovits JE; Lyons RM; Kaleko M; Stevenson SC
    Hum Gene Ther; 2003 Nov; 14(17):1595-604. PubMed ID: 14633402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.
    Jogler C; Hoffmann D; Theegarten D; Grunwald T; Uberla K; Wildner O
    J Virol; 2006 Apr; 80(7):3549-58. PubMed ID: 16537623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
    Ogata K; Mimuro J; Kikuchi J; Tabata T; Ueda Y; Naito M; Madoiwa S; Takano K; Hasegawa M; Ozawa K; Sakata Y
    Gene Ther; 2004 Feb; 11(3):253-9. PubMed ID: 14737084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice.
    Bristol JA; Shirley P; Idamakanti N; Kaleko M; Connelly S
    Mol Ther; 2000 Sep; 2(3):223-32. PubMed ID: 10985953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A.
    Zhang WW; Josephs SF; Zhou J; Fang X; Alemany R; Balagué C; Dai Y; Ayares D; Prokopenko E; Lou YC; Sethi E; Hubert-Leslie D; Kennedy M; Ruiz L; Rockow-Magnone S
    Thromb Haemost; 1999 Aug; 82(2):562-71. PubMed ID: 10605752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoter.
    Picanço V; Heinz S; Bott D; Behrmann M; Covas DT; Seifried E; Tonn T
    Cytotherapy; 2007; 9(8):785-94. PubMed ID: 17917890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.